Global DTaP and Tdap Vaccines Market Insights, Forecast to 2025

Price

1-user PDF: $3900.0  
Site PDF: $5850.0  
Enterprise PDF: $7800.0

Description:

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTaP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement. Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaranacel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

The global DTaP and Tdap Vaccines market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the DTaP and Tdap Vaccines market based on company, product type, end user and key regions. This report studies the global market size of DTaP and Tdap Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa. The report also focuses on the consumption of DTaP and Tdap Vaccines in these regions. This research report categorizes the global DTaP and Tdap Vaccines market by top players/brands, region, type and end user. This report also studies the global DTaP and Tdap Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Sanofi Pasteur
GlaxoSmithKline
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Market size by Product
DTaP
Tdap
Market size by End User
Adult
Pediatric
Market size by Region
North America
United States
Canada
The study objectives of this report are:

To study and analyze the global DTaP and Tdap Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of DTaP and Tdap Vaccines market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global DTaP and Tdap Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of DTaP and Tdap Vaccines submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of DTaP and Tdap Vaccines are as follows:

History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of DTaP and Tdap Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents:

Table of Contents

1 Study Coverage
   • 1.1 DTaP and Tdap Vaccines Product
   • 1.2 Market Segments
   • 1.3 Key Manufacturers Covered
   • 1.4 Market by Type
     • 1.4.1 Global DTaP and Tdap Vaccines Market Size Growth Rate by Product
     • 1.4.2 DTaP
     • 1.4.3 Td
     • 1.4.4 Tdap
   • 1.5 Market by End User
     • 1.5.1 Global DTaP and Tdap Vaccines Market Size Growth Rate by End User
     • 1.5.2 Adult
     • 1.5.3 Pediatric
   • 1.6 Study Objectives
   • 1.7 Years Considered

2 Executive Summary
   • 2.1 Global DTaP and Tdap Vaccines Market Size
     • 2.1.1 Global DTaP and Tdap Vaccines Revenue 2014-2025
     • 2.1.2 Global DTaP and Tdap Vaccines Sales 2014-2025
   • 2.2 DTaP and Tdap Vaccines Growth Rate by Regions
     • 2.2.1 Global DTaP and Tdap Vaccines Sales by Regions
     • 2.2.2 Global DTaP and Tdap Vaccines Revenue by Regions

3 Breakdown Data by Manufacturers
   • 3.1 DTaP and Tdap Vaccines Sales by Manufacturers
     • 3.1.1 DTaP and Tdap Vaccines Sales by Manufacturers
     • 3.1.2 DTaP and Tdap Vaccines Sales Market Share by Manufacturers
     • 3.1.3 Global DTaP and Tdap Vaccines Market Concentration Ratio (CR5 and HHI)
   • 3.2 DTaP and Tdap Vaccines Revenue by Manufacturers
     • 3.2.1 DTaP and Tdap Vaccines Revenue by Manufacturers (2014-2019)
     • 3.2.2 DTaP and Tdap Vaccines Revenue Share by Manufacturers (2014-2019)
3.3 DTaP and Tdap Vaccines Price by Manufacturers
3.4 DTaP and Tdap Vaccines Manufacturing Base Distribution, Product Types
  3.4.1 DTaP and Tdap Vaccines Manufacturers Manufacturing Base Distribution, Headquarters
  3.4.2 Manufacturers DTaP and Tdap Vaccines Product Type
  3.4.3 Date of International Manufacturers Enter into DTaP and Tdap Vaccines Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
  4.1 Global DTaP and Tdap Vaccines Sales by Product
  4.2 Global DTaP and Tdap Vaccines Revenue by Product
  4.3 DTaP and Tdap Vaccines Price by Product

5 Breakdown Data by End User
  5.1 Overview
  5.2 Global DTaP and Tdap Vaccines Breakdown Data by End User

6 North America
  6.1 North America DTaP and Tdap Vaccines by Countries
    6.1.1 North America DTaP and Tdap Vaccines Sales by Countries
    6.1.2 North America DTaP and Tdap Vaccines Revenue by Countries
  6.1.3 United States
    6.1.4 Canada
    6.1.5 Mexico
  6.2 North America DTaP and Tdap Vaccines by Product
  6.3 North America DTaP and Tdap Vaccines by End User

7 Europe
  7.1 Europe DTaP and Tdap Vaccines by Countries
    7.1.1 Europe DTaP and Tdap Vaccines Sales by Countries
    7.1.2 Europe DTaP and Tdap Vaccines Revenue by Countries
  7.1.3 Germany
    7.1.4 France
    7.1.5 UK
    7.1.6 Italy
    7.1.7 Russia
  7.2 Europe DTaP and Tdap Vaccines by Product
  7.3 Europe DTaP and Tdap Vaccines by End User

8 Asia Pacific
  8.1 Asia Pacific DTaP and Tdap Vaccines by Countries
    8.1.1 Asia Pacific DTaP and Tdap Vaccines Sales by Countries
    8.1.2 Asia Pacific DTaP and Tdap Vaccines Revenue by Countries
    8.1.3 China
    8.1.4 Japan
    8.1.5 Korea
    8.1.6 India
    8.1.7 Australia
    8.1.8 Indonesia
    8.1.9 Malaysia
    8.1.10 Philippines
    8.1.11 Thailand
    8.1.12 Vietnam
    8.1.13 Singapore
  8.2 Asia Pacific DTaP and Tdap Vaccines by Product
  8.3 Asia Pacific DTaP and Tdap Vaccines by End User

9 Central & South America
  9.1 Central & South America DTaP and Tdap Vaccines by Countries
    9.1.1 Central & South America DTaP and Tdap Vaccines Sales by Countries
    9.1.2 Central & South America DTaP and Tdap Vaccines Revenue by Countries
    9.1.3 Brazil
  9.2 Central & South America DTaP and Tdap Vaccines by Product
  9.3 Central & South America DTaP and Tdap Vaccines by End User

10 Middle East and Africa
  10.1 Middle East and Africa DTaP and Tdap Vaccines by Countries
    10.1.1 Middle East and Africa DTaP and Tdap Vaccines Sales by Countries
    10.1.2 Middle East and Africa DTaP and Tdap Vaccines Revenue by Countries
    10.1.3 GCC Countries
    10.1.4 Turkey
    10.1.5 Egypt
    10.1.6 South Africa
  10.2 Middle East and Africa DTaP and Tdap Vaccines by Product
  10.3 Middle East and Africa DTaP and Tdap Vaccines by End User

11 Company Profiles
  11.1 Sanofi Pasteur
    11.1.1 Sanofi Pasteur Company Details
    11.1.2 Company Business Overview
    11.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
    11.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Products Offered
    11.1.5 Sanofi Pasteur Recent Development
  11.2 GlaxoSmithKline
    11.2.1 GlaxoSmithKline Company Details
    11.2.2 Company Business Overview
    11.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
    11.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Products Offered
11.2.5 GlaxoSmithKline Recent Development

11.3 Protein Sciences Corporation
- 11.3.1 Protein Sciences Corporation Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Products Offered
- 11.3.5 Protein Sciences Corporation Recent Development

11.4 Novartis AG
- 11.4.1 Novartis AG Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Novartis AG DTaP and Tdap Vaccines Products Offered
- 11.4.5 Novartis AG Recent Development

11.5 Seqirus
- 11.5.1 Seqirus Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Seqirus DTaP and Tdap Vaccines Products Offered
- 11.5.5 Seqirus Recent Development

11.6 Merck Sharp & Dohme Corp
- 11.6.1 Merck Sharp & Dohme Corp Company Details
- 11.6.2 Company Business Overview
- 11.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Products Offered
- 11.6.5 Merck Sharp & Dohme Corp Recent Development

11.7 Astellas Pharma US, Inc
- 11.7.1 Astellas Pharma US, Inc Company Details
- 11.7.2 Company Business Overview
- 11.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Products Offered
- 11.7.5 Astellas Pharma US, Inc Recent Development

11.8 Pfizer Inc
- 11.8.1 Pfizer Inc Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Pfizer Inc DTaP and Tdap Vaccines Products Offered
- 11.8.5 Pfizer Inc Recent Development

11.9 Johnson & Johnson
- 11.9.1 Johnson & Johnson Company Details
- 11.9.2 Company Business Overview
- 11.9.4 Johnson & Johnson DTaP and Tdap Vaccines Products Offered
- 11.9.5 Johnson & Johnson Recent Development

11.10 Lanzhou Institute of Biological Products Co., Ltd
- 11.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Products Offered
- 11.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development

11.11 AstraZeneca

11.12 Emergent BioSolutions Inc

12 Future Forecast
- 12.1 DTaP and Tdap Vaccines Market Forecast by Regions
- 12.1.1 Global DTaP and Tdap Vaccines Sales Forecast by Regions 2019-2025
- 12.1.2 Global DTaP and Tdap Vaccines Revenue Forecast by Regions 2019-2025
- 12.2 DTaP and Tdap Vaccines Market Forecast by Product
- 12.2.1 Global DTaP and Tdap Vaccines Sales Forecast by Product 2019-2025
- 12.2.2 Global DTaP and Tdap Vaccines Revenue Forecast by Product 2019-2025
- 12.3 DTaP and Tdap Vaccines Market Forecast by End User
- 12.4 North America DTaP and Tdap Vaccines Forecast
- 12.5 Europe DTaP and Tdap Vaccines Forecast
- 12.6 Asia Pacific DTaP and Tdap Vaccines Forecast
- 12.7 Central & South America DTaP and Tdap Vaccines Forecast
- 12.8 Middle East and Africa DTaP and Tdap Vaccines Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 DTaP and Tdap Vaccines Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details